{"id":"NCT01426854","sponsor":"Alcon Research","briefTitle":"Nepafenac Compared to Placebo for Ocular Pain and Inflammation","officialTitle":"Clinical Evaluation of Safety and Efficacy of Nepafenac Ophthalmic Suspension, 0.1% Compared to Placebo for the Prevention and Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery in Adult Chinese Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2012-04","completion":"2012-04","firstPosted":"2011-09-01","resultsPosted":"2013-05-13","lastUpdate":"2013-05-13"},"enrollment":260,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Cataract"],"interventions":[{"type":"DRUG","name":"Nepafenac Ophthalmic Suspension, 0.1%","otherNames":[]},{"type":"OTHER","name":"Nepafenac Vehicle Ophthalmic Solution","otherNames":[]}],"arms":[{"label":"Nepafenac","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to demonstrate that Nepafenac Ophthalmic Suspension, 0.1% is superior to Nepafenac Vehicle (placebo) for the prevention and treatment of ocular inflammation and pain associated with cataract surgery in Chinese subjects.","primaryOutcome":{"measure":"Proportion of Subjects With Clinical Cure at Day 14","timeFrame":"Day 14 postoperative","effectByArm":[{"arm":"Nepafenac","deltaMin":80.3,"sd":null},{"arm":"Placebo","deltaMin":39.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":24},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":125},"commonTop":[]}}